{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:16:52Z","timestamp":1788675412356,"version":"build-2803163510"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Symptomatic hyperprolactinemia is rarely seen in children, particularly among those with complex neurodevelopmental disorders. While risperidone is known to raise prolactin levels, cases with clear clinical symptoms are uncommon. This report describes an unusual presentation of hyperprolactinemia in a 12-year-old girl with Landau\u2013Kleffner syndrome, autism spectrum disorder, and intellectual disability, whose symptoms closely resembled pituitary pathology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>The 12-year-old Hispanic Peruvian female was under long-term behavioral control therapy of risperidone. With time, she got galactorrhea, visual impairments, and falls. Laboratory revealed high serum prolactin (40.2 ng\/mL) and normal thyroid and negative beta-hCG level. No pituitary lesion was seen on neuroimaging. Behavioral symptoms increased following the discontinuation of risperidone, after which the substitution of the latter with olanzapine led to complete restoration. Three months later galactorrhea disappeared, vision improved, and prolactin level was restored (2.2 ng\/mL). The mother of the patient was relieved to find out that it was a medication-related issue, but not a tumor and indicated a significant enhancement in the overall behavior and quality of life of her child.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The case shows the significance of following prolactin levels in children who are on risperidone therapy particularly those who are non-verbal or those who cannot communicate any discomfort. Clinicians are to remember that risperidone leads to hyperprolactinemia which can simulate pituitary malfunctions. Early identification, educating caregivers, and substitution of prolactin-stimulating drugs with prolactin-sparing ones like olanzapine will allow avoiding unnecessary investigations and enhancing the clinical and family outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-026-06181-x","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:14:18Z","timestamp":1782134058000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Symptomatic hyperprolactinemia mimicking pituitary pathology in a child with Landau\u2013Kleffner syndrome, autism spectrum disorder, and intellectual disability: a case report"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9116-6519","authenticated-orcid":false,"given":"Swetang J.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viral","family":"Goradia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aahna V.","family":"Dattani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sireesha","family":"Palkamsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshuman","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"9","key":"6181_CR1","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ng.2726","volume":"45","author":"G Lesca","year":"2013","unstructured":"Lesca G, Rudolf G, Bruneau N, Lozovaya N, Labalme A, Boutry-Kryza N, et al. GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet. 2013;45(9):1061\u20136. https:\/\/doi.org\/10.1038\/ng.2726.","journal-title":"Nat Genet"},{"issue":"4","key":"6181_CR2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","volume":"61","author":"GM Anderson","year":"2007","unstructured":"Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E, et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry. 2007;61(4):545\u201350. https:\/\/doi.org\/10.1016\/j.biopsych.2006.02.032.","journal-title":"Biol Psychiatry"},{"key":"6181_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/159402","volume":"2010","author":"AL Rosenbloom","year":"2010","unstructured":"Rosenbloom AL. Hyperprolactinemia with antipsychotic drugs in children and adolescents. Int J Pediatr Endocrinol. 2010;2010: 159402. https:\/\/doi.org\/10.1155\/2010\/159402.","journal-title":"Int J Pediatr Endocrinol"},{"issue":"6","key":"6181_CR4","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1089\/cap.2005.15.885","volume":"15","author":"JA Hellings","year":"2005","unstructured":"Hellings JA, Zarcone JR, Valdovinos MG, Reese RM, Gaughan E, Schroeder SR. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2005;15(6):885\u201392. https:\/\/doi.org\/10.1089\/cap.2005.15.885.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"6181_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/01.jcp.0000203194.58087.9a","volume":"26","author":"L Holzer","year":"2006","unstructured":"Holzer L, Eap CB. Risperidone-induced symptomatic hyperprolactinemia in adolescents. J Clin Psychopharmacol. 2006;26(2):167\u201371. https:\/\/doi.org\/10.1097\/01.jcp.0000203194.58087.9a.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"6181_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4274\/jcrpe.v3i2.14","volume":"3","author":"E Eren","year":"2011","unstructured":"Eren E, Yap\u0131c\u0131 \u015e, \u00c7ak\u0131r EDP, Aycan Z. Clinical course of hyperprolactinemia in children and adolescents: a review of 21 cases. J Clin Res Pediatr Endocrinol. 2011;3(2):65\u20139. https:\/\/doi.org\/10.4274\/jcrpe.v3i2.14.","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"1","key":"6181_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-251974","volume":"16","author":"J Lee","year":"2023","unstructured":"Lee J, Shepperd R, Smith M, Anand G. Recognising side effects of antipsychotics in children with intellectual disabilities. BMJ Case Rep. 2023;16(1): e251974. https:\/\/doi.org\/10.1136\/bcr-2022-251974.","journal-title":"BMJ Case Rep"},{"key":"6181_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2147\/NDT.S76276","volume":"11","author":"Y Hongkaew","year":"2015","unstructured":"Hongkaew Y, Ngamsamut N, Puangpetch A, Vanwong N, Srisawasdi P, Chamnanphon M, et al. Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone. Neuropsychiatr Dis Treat. 2015;11:191\u20136. https:\/\/doi.org\/10.2147\/NDT.S76276.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"6181_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.9740\/mhc.2016.07.185","volume":"6","author":"A Tewksbury","year":"2016","unstructured":"Tewksbury A, Olander A. Management of antipsychotic-induced hyperprolactinemia. Ment Health Clin. 2016;6(4):185\u201390. https:\/\/doi.org\/10.9740\/mhc.2016.07.185.","journal-title":"Ment Health Clin"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06181-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06181-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06181-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:55:55Z","timestamp":1788393355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-026-06181-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6181"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-06181-x","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required for this single case report, in accordance with the institutional\/national policy.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient's legal guardian for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"518"}}